These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32653806)

  • 21. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.
    Chan TSY; Li J; Loong F; Khong PL; Tse E; Kwong YL
    Ann Hematol; 2018 Jan; 97(1):193-196. PubMed ID: 28879531
    [No Abstract]   [Full Text] [Related]  

  • 22. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sinonasal relapses of a primary isolated extranodal NK/T-cell lymphoma of the testis.
    Hallak B; Cairoli A; Bouayed S; Berthod G
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31413056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database.
    Liu X; Zhang LL; Qu BL; Zhong QZ; Qian LT; Yang Y; Hou XR; Qiao XY; Wang H; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Zhang XM; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Wang Y; Chen F; Yin L; He X; Cai S; Li YX; Qi SN
    Haematologica; 2023 Sep; 108(9):2467-2475. PubMed ID: 36951150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
    Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
    BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CD16 expression is an independent prognostic factor for extranodal NK/T cell lymphoma of nasal type].
    Zuo Z; Yang QP; Tang Y; Zhao S; Yu JB; Liu YM; Gao LM; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):227-33. PubMed ID: 23928528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
    Deng XW; Wu JX; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Dong M; Qi SN; Yang Y; Li YX
    Radiother Oncol; 2018 Oct; 129(1):3-9. PubMed ID: 29739712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extranodal NK/T cell lymphoma, nasal type: An updated overview.
    Sánchez-Romero C; Bologna-Molina R; Paes de Almeida O; Santos-Silva AR; Prado-Ribeiro AC; Brandão TB; Carlos R
    Crit Rev Oncol Hematol; 2021 Mar; 159():103237. PubMed ID: 33493634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?
    Costa RO; Pereira J; Lage LAPC; Baiocchi OCG
    Front Oncol; 2023; 13():1175545. PubMed ID: 37529691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation.
    McEachron TA; Kirov I; Wungwattana M; Cortes D; Zabokrtsky KB; Sassoon A; Craig D; Carpten JD; Sender LS
    Pediatr Blood Cancer; 2016 Apr; 63(4):727-30. PubMed ID: 26727971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK-Cell Lymphomas.
    Chihara D; Oki Y
    Cancer Treat Res; 2019; 176():163-184. PubMed ID: 30596218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances of treatment for extranodal NK/T-cell lymphoma --- review].
    Zhang SS; Wei M; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1075-8. PubMed ID: 21867647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
    Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
    [No Abstract]   [Full Text] [Related]  

  • 34. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of asparagine synthetase in relapsed or refractory extranodal NK/T cell lymphoma].
    Wu SJ; Li YF; Wang YJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):465-469. PubMed ID: 28446397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NK/T Cell Lymphoma: Updates in Therapy.
    Suzuki R
    Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
    Tse E; Kwong YL
    Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
    Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
    Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility of low-dose radiotherapy for patients with stage I/II extranodal NK-/
    Kim JS; Choi N; Kim IH; Kim TM; Jeon YK; Chang JH
    Clin Transl Radiat Oncol; 2023 Jan; 38():155-160. PubMed ID: 36466747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.